PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M

PAVmed Inc.

2025-Q1 EPS reported $0.34 revenue$8,000

GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).
Lucid Diagnostics (LUCD) recognized $0.8M EsoGuard revenue, processed 3,034 tests; raised $30.6M net from stock offerings, ended Q1 with over $40M pro forma cash.
Veris Health completed financing, resumed development of implantable monitor; completed pilot with Ohio State's James Cancer Hospital, planning commercial partnership.
PAVmed cash and cash equivalents $2.7M at March 31, 2025, up from $1.2M at Dec 31, 2024; operating expenses $5.5M including $1.0M stock-based comp.
PAVmed seeking to expand into biopharma, evaluating clinical and late preclinical-stage assets for new subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.